Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
27.44
+0.01 (0.04%)
Dec 2, 2025, 11:11 AM EST - Market open
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Mersana Therapeutics stock have a consensus rating of "Buy" and an average price target of $30.38, which forecasts a 10.71% increase in the stock price over the next year. The lowest target is $30 and the highest is $30.75.
Price Target: $30.38 (+10.71%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $36 → $31 | Strong Buy → Hold | Downgrades | $36 → $31 | +12.06% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 13, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $250 → $36 | Strong Buy | Maintains | $250 → $36 | +31.20% | Aug 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +9.33% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
25.80M
from 40.50M
Decreased by -36.29%
Revenue Next Year
20.09M
from 25.80M
Decreased by -22.12%
EPS This Year
-8.88
from -14.12
EPS Next Year
-10.65
from -8.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.8M | 44.9M | ||||
| Avg | 25.8M | 20.1M | ||||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -6.7% | 74.2% | ||||
| Avg | -36.3% | -22.1% | ||||
| Low | -63.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.64 | -0.79 | |
| Avg | -8.88 | -10.65 | |
| Low | -15.97 | -16.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.